(CTXR)
0.00
0.00 (0.00%)
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
0.00
0.00 (0.00%)
Citius Pharmaceuticals, Inc., biotexnologiya kompaniyasi, intensiv terapiya mahsulotlarini ishlab chiqish va tijoratlashtirishga qaratilgan. FDA tomonidan tasdiqlangan LYMPHIR mahsuloti, teri T-hujayrali limfoma davolash uchun mo'ljallangan immunoterapiya hisoblanadi. Kompaniyaning keyingi bosqichdagi mahsulotlari qatoriga kateter bilan bog'liq qon oqimi infeksiyalarini davolash uchun antibiotik blokirovka eritmasi bo'lgan Mino-Lok; gemorroydan aziyat chekayotgan shaxslarga yallig'lanishga qarshi va og'riqsizlantiruvchi yordam ko'rsatish uchun kortikosteroid-lidokainli topik preparat bo'lgan Halo-Lido; va ARDSni davolash uchun mezenxima ildiz hujayralari terapiyasi bo'lgan NoveCite kiradi. Citius Pharmaceuticals, Inc. 2007-yilda tashkil etilgan va Nyu-Jersi shtatining Cranford shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alan Lader Ph.D. | Senior VP and Head of Clinical Operations & Quality Assurance |
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer |
| Mr. Dhananjay G. Wadekar | Senior Vice President of Business Strategy |
| Mr. Gary F. Talarico | Executive Vice President of Operations |
| Mr. Jaime Bartushak | Chief Business Officer & CFO |
| Mr. Kelly Creighton Ph.D. | Executive Vice President of Chemistry, Manufacturing & Controls |
| Mr. Leonard L. Mazur | Co-Founder, CEO, Chairman & Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-10 | 8-K | ea0280664-8k_citius.htm |
| 2026-03-04 | 8-K | ea0277422-8k_citius.htm |
| 2026-01-28 | 10-K/A | ea0273793-10ka1_citius.htm |
| 2025-12-23 | 8-K | ea0270776-8k_citius.htm |
| 2025-12-01 | 8-K | ea0267562-8k_citius.htm |
| 2025-10-23 | 8-K | ea0262321-8k_citius.htm |
| 2025-10-21 | 8-K | ea0261909-8k_citius.htm |
| 2025-08-12 | 8-K | ea0252899-8k_citius.htm |
| 2025-07-08 | 8-K | ea0248335-8k_citius.htm |
| 2025-06-12 | 8-K | ea0245241-8k_citius.htm |
| Mr. Myron Z. Holubiak | Co-Founder & Executive Vice Chairman |
| Mr. Nikolas Burlew | Executive Vice President of Quality Assurance |
| Ms. Ilanit Allen | Vice President of Investor Relations & Corporate Communications |